CLDXCelldex Therapeutics, Inc.

$2B

FY 2011 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-80.2% YoY

Gross Profit

$146,0001.6% margin

Operating Income

-$43M-468.4% margin

Net Income

-$45M-483.5% margin

EPS (Diluted)

$-17.01

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$36M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$98M

Total Liabilities

$29M

Stockholders' Equity

$69M

Cash & Equivalents

$12M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$47M	-80.2%
Gross Profit	$146,000	$35M	-99.6%
Operating Income	-$43M	-$6M	-572.3%
Net Income	-$45M	-$3M	-1668.6%

CLDX FY 2011 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena